Clinical Trial

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 19, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the Safety and Efficacy of Neoadjuvant study of DV in combination Toripalimab i or sequence chemotherapy in HR-negative, HER2 low-expressing Breast Cancer
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-01-17; most recent amendment 2024-03-15.
Status change: Not Yet Recruiting → Recruiting 2024-02-18
Trial Details
NCT Number NCT06227117
Lead Sponsor RemeGen Co., Ltd.
Conditions Breast Cancer
Enrollment 120 participants
Start Date 2023-07-27
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-03-19